ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients.
“Our team is excited to begin serving our home state of California, and its nearly 40 million residents, with high-quality ophthalmic formulations from our FDA-registered 503B outsourcing facility,” John Saharek, President of ImprimisRx, said. “We are grateful the State of California has issued this permit, one that has been granted to only a select few of the outsourcing facilities registered with the FDA.”